Dendritic cell-based immunotherapy (DC vaccine) (DC vaccine)

Dendritic cell-based immunotherapy is a personalized cancer treatment that utilizes a patient's own immune cells to identify and attack malignant tissues (Palucka & Banchereau, 2012, Nature Reviews Cancer). Dendritic cells (DCs) are harvested from the patient's blood, typically through leukapheresis, and are then matured and loaded with tumor-associated antigens (TAAs) or tumor lysates in a laboratory setting (Anguille et al., 2014, Lancet Oncology). These activated DCs are re-infused into the patient, where they travel to the lymph nodes to act as professional antigen-presenting cells. Within the lymph nodes, the DCs present the tumor antigens to naive T cells via Major Histocompatibility Complex (MHC) class I and II molecules, which is essential for the priming of CD8+ cytotoxic T lymphocytes and CD4+ helper T cells (Banchereau & Steinman, 1998, Nature). This process triggers a systemic, multi-antigenic immune response designed to overcome the immunosuppressive environment often created by tumors. Unlike conventional drugs that target a single receptor or enzyme, this cellular therapy leverages the natural complexity of the immune system to target diverse tumor antigens. The most prominent example of this technology is Sipuleucel-T, which was the first FDA-approved autologous cellular immunotherapy for metastatic castration-resistant prostate cancer (Kantoff et al., 2010, NEJM). While generally well-tolerated, the therapy faces challenges such as high manufacturing costs and logistical complexity.

Other names

Autologous dendritic cell vaccineDC-based vaccineAntigen-presenting cell therapyCellular immunotherapyDendritic cell therapy

Patient-derived dendritic cells are harvested and loaded ex vivo with tumor-associated antigens (TAAs) or tumor lysates; upon re-infusion, these cells migrate to lymphoid tissues and present the antigens via MHC Class I and II molecules to T-cell receptors, thereby priming and activating a tumor-specific cytotoxic T-cell response.